Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romosozumab - Amgen/UCB

Next Previous
Drug Profile

Romosozumab - Amgen/UCB

Alternative Names: AMG-785; Anti-sclerostin; Anti-sclerostin monoclonal antibody; CDP-7851; EVENITY; romosozumab-aqqg; Sclerostin Ab

Latest Information Update: 16 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChiroscienceGroup plc
  • Developer Amgen; UCB
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis
  • Phase III Osteogenesis imperfecta; Osteoporosis
  • Discontinued Fracture

Most Recent Events

  • 10 Sep 2026 Amgen plans a phase I trial in healthy volunteers in USA in September 2026 (SC) (NCT07811999)
  • 17 Jun 2026 Launched for Male osteoporosis in Switzerland (SC)
  • 17 Jun 2026 Launched for Postmenopausal osteoporosis in United Kingdom, United Arab Emirates, Singapore, Malaysia, Malaysia, Turkey, Norway, Israel, Israel, Ireland, Hong Kong, Sweden, Austria, Sweden, Poland, Netherlands, Netherlands, Hungary, Greece, Germany, Denmark, Brazil, Brazil, Belgium, Argentina (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top